The Watermark At Bellingham Park Lane | |
1615 East Boot Road East Goshen, West Chester, Pennsylvania 19380 | |
(484) 653-4400 | |
Name | The Watermark At Bellingham Park Lane |
---|---|
Location | 1615 East Boot Road East Goshen, West Chester, Pennsylvania |
Certified By | Medicare |
No. of Certified Beds | 64 |
Occupancy Rate | 51.41% |
Medicare ID (CCN) | 396082 |
Legal Business Name | Watermark Park Lane, Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1053456038 |
Organization Name | SL BELLINGHAM SNF LLC |
Doing Business As | PARK LANE AT BELLINGHAM |
Address | 1615 E Boot Rd, West Chester, PA 19380 |
Phone Number | 484-653-4400 |
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
NPI Number | 1215189147 |
Address | 1615 E Boot Rd, West Chester, PA 19380 |
Phone Number | 484-653-4426 |
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
NPI Number | 1376150409 |
Organization Name | WATERMARK PARK LANE, LLC |
Address | 1615 E Boot Rd, West Chester, PA 19380 |
Phone Number | 484-714-0490 |
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
NPI Number | 1760479109 |
Organization Name | PARK LANE AT BELLINGHAM |
Address | 1615 E Boot Rd, West Chester, PA 19380 |
Phone Number | 484-653-4400 |
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
NPI Number | 1821543323 |
Address | 1615 E Boot Rd, West Chester, PA 19380 |
Phone Number | 484-887-2209 |
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening conditions, announced the launch of its International CytoSorb Treatment Registry, established and managed by the Center of Clinical Trials at the University of Jena, Germany.
With an expanded focus on addressing peripheral arterial disease (PAD), Medtronic, Inc. (NYSE: MDT), today announced that it has completed enrollment in a clinical trial of the company's Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the superficial femoral artery (SFA), including the proximal popliteal artery (PPA), which runs under the skin of the thigh.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
The Developmental Origins of Health and Disease (DOHaD) hypothesis is supported by multiple human epidemiological studies and animal studies.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 24.62 | 14.46 |
Percentage of long-stay residents who lose too much weight | 19.05 | 5.51 |